Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Call Transcript February 29, 2024
Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.26. CRDF isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Welcome to the Cardiff Oncology Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only...
